Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain.[1] Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.[2]

Fentiazac
Clinical data
Trade namesNorvedan
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.038.129 Edit this at Wikidata
Chemical and physical data
FormulaC17H12ClNO2S
Molar mass329.80 g·mol−1
3D model (JSmol)
Melting point162–163 °C (324–325 °F)
  • c1ccc(cc1)c2nc(c(s2)CC(=O)O)c3ccc(cc3)Cl
  • InChI=1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21) ☒N
  • Key:JIEKMACRVQTPRC-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.[3]

See also

edit

References

edit
  1. ^ Lombardino JG (1985). Nonsteroidal antiinflammatory drugs. Vol. 247. New York: Wiley. p. 285. ISBN 978-0-471-89803-0.
  2. ^ Brown K, Cater DP, Cavalla JF, Green D, Newberry RA, Wilson AB (November 1974). "Nonsteroidal antiinflammatory agents. 1.2,4-Diphenylthiazole-5-acetic acid and related compounds". Journal of Medicinal Chemistry. 17 (11): 1177–1181. doi:10.1021/jm00257a010. PMID 4414839.
  3. ^ "FENTIAZAC". NCATS Inxight Drugs. National Center for Advancing Translational Sciences (NCATS); U.S. National Institutes of Health. Retrieved 2023-06-08.